Latent TB Infection Therapy in Dialysis Patients are Considered Safe but Requires Close Monitoring, Study Shows

A recent study shows that many patients receiving maintenance dialysis can complete latent tuberculosis (TB) infection (LTBI) therapy. Although, the risk of high-grade averse events (AEs) is high and related to frequent medication changes during therapy.

Photo: Dialysis Patient | InStyleHealth


Historical group study covered 365 patients who had undergone at least 90 days of dialysis and initiated LTBI therapy. There were 290 (79.5%) people were in the recent study (2012 onwards) and 75 (20.5%) were in the historical group (before 2012).

To report the outcomes of the study, experts used the descriptive statistics. Two-sample test of proportions using χ2 distribution was applied to test for statistical significance between the recent and historical groups.

The majority of the population successfully completed LTBI therapy. Overall, 21.1% of patients developed a grade 3 to 4 AE or rash of any grade. Most adverse events were related to gastrointestinal events, general malaise, or pruritus that led to changes in their treatment regimen. There were 2 patients were hospitalized for adverse events (AEs) related to LTBI therapy.

No significant differences were observed between the recent and historical groups in all outcomes of interest according to researchers. Also, none of grade 5 AEs (deaths) documented were attributed to LTBI therapy.

Patients on maintenance dialysis are at an increased risk of active TB, and the present data indicate that LTBI therapy in this group can be safe but requires close monitoring.

Researchers noted that the study was limited by the retrospective nature of data and generalizability outside low-TB-burden settings.

 

 

Source: Am J Kidney Dis 2021;77:696-703

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post